Characteristic | Total (N) | YAP1 mRNA expression relative to GAPDH | p value |
---|---|---|---|
Normal | 137 | 2.27 ± 1.65 | 0.0001 |
Tumor | 137 | 0.11 ± 5.60 |  |
Age (years) | |||
≤50 | 78 (56.93) | 0.149 ± 0.00 | 0.464 |
>50 | 59 (43.07) | 0.053 ± 0.00 |  |
Age at menarche | |||
≤12 | 26 (18.98) | 0.033 ± 0.00 | 0.524 |
>12 | 111 (81.02) | 0.125 ± 0.00 |  |
Menopausal status | |||
Premenopausal | 40 (29.20) | 0.036 ± 0.00 | 0.462 |
Postmenopausal | 97 (70.80) | 0.137 ± 0.00 |  |
Age at menopause | |||
≤45 | 33 (34.02) | 0.297 ± 1.09 | 0.281 |
>45 | 64 (65.98) | 0.055 ± 1.98 |  |
ER status | |||
Positive | 81 (59.12) | 0.121 ± 0.00 | 0.373 |
Negative | 56 (40.88) | 0.088 ± 0.00 |  |
PR status | |||
Positive | 47 (34.31) | 0.141 ± 0.00 | 0.741 |
Negative | 90 (65.69) | 0.090 ± 0.00 |  |
Her2 status | |||
Positive | 66 (48.18) | 0.053 ± 0.00 | 0.506 |
Negative | 71 (51.82) | 0.159 ± 0.00 |  |
Molecular subtypes of breast cancer | |||
Luminal A | 46 (33.58) | 0.149 ± 0.00 | 0.731 |
Luminal B | 38 (27.74) | 0.079 ± 0.00 |  |
Her2-enriched | 28 (20.44) | 0.018 ± 0.00 |  |
TNBC | 25 (18.25) | 0.178 ± 0.00 |  |
Tumor size | |||
≤5 | 55 (40.15) | 0.183 ± 0.00 | 0.169 |
>5 | 82 (59.85) | 0.057 ± 0.00 |  |
Lymph node status | |||
Positive | 99 (72.26) | 0.109 ± 0.00 | 0.203 |
Negative | 38 (27.74) | 0.103 ± 0.00 |  |
Clinical stage | |||
I+II | 45(32.85) | 0.206 ± 0.00 | 0.038 |
III+IV | 92(67.15) | 0.06 ± 0.00 |  |
Histological grade | |||
I+II | 95 (69.34) | 0.096 ± 0.00 | 0.869 |
III | 42 (30.66) | 0.135 ± 0.00 |  |